Clinical Trials

Study Title

Expanded Access to Convalescent Plasma for the Treatment of Patients with COVID-19

Purpose

Provide access to COVID-19 convalescent plasma

Eligibility

Age at least 18 y/o

Laboratory confirmed diagnosis of infection with SARS-CoV-2 

 Admitted to an acute care facility for the treatment of COVID-19 complications

Severe or life threatening COVID-19, or judged by the treating provider to be at high risk of progression to severe or life-threatening disease

Informed consent provided by the patient or healthcare proxy Severe COVID-19 is defined by one or more of the following: ·         dyspnea

respiratory frequency ≥ 30/min

blood oxygen saturation ≤ 93%

partial pressure of arterial oxygen to fraction of inspired oxygen ratio < 300

lung infiltrates > 50% within 24 to 48 hours

Life-threatening COVID-19 is defined as one or more of the following:

respiratory failure

septic shock

multiple organ dysfunction or failure

Study Process

One of the ways that people fight off infectious diseases is by developing antibodies that lead to the destruction of the invading microorganism. The antibodies are present in the blood, and more specifically in the liquid portion of the blood called plasma. People who have recovered from being recently infected can donate plasma and that plasma can then be given to individuals who are ill with the virus in order to try to help eliminate it from the system and allow them to get better. This has worked in previous outbreaks of respiratory diseases like influenza, and there are some early data to suggest that it might work for some people with COVID-19.

** IF YOU HAVE TESTED POSITIVE FOR COVID-19 AND RECOVERED WITH AT LEAST 14 DAYS SINCE YOU HAVE HAD SYMPTOMS, PLEASE CONSIDER DONATING PLASMA.  CONTACT YOUR PRIMARY CARE PHYSICIAN OR THE NUMBER BELOW FOR DETAILS**